This document provides a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV in PLC3 differentiated cells using qPCR.
This document outlines a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV using qPCR in PLC3 differentiated cells.
When evaluating the antiviral effect of a compound, assessing cellular toxicity in the target cell line is an essential prerequisite (see SOP ‘AVITHRAPID - Standard Operating Procedure - Cytotoxicity evaluation – virucidal compounds’ at https://zenodo.org/records/20486126). The highest dose allowing > 90 % cell viability is the first tested dose in antiviral assay. Quantifying viruses in the supernatants of infected cell cultures enables the evaluation of the antiviral efficacy of compounds. PLC3 differenciated cells are used for HEV infection studies.
Anne Bull-Maurer (Mon,) conducted a other in HEV infection (in vitro). Virucidal compounds was evaluated on Antiviral efficacy (quantifying viruses in supernatants by qPCR). This document provides a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV in PLC3 differentiated cells using qPCR.